SCHEMBL4168482

SCHEMBL4168482

Cc1cc(S(N)(=O)=O)c(C=C2c3ccccc3CCc3ccccc32)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 1/20 0.42
PGR P06401 1/20 0.42
NR3C2 P08235 1/20 0.42
AR P10275 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.38
NPC1 O15118 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
RAB9A P51151 2/20 0.38
PKM P14618 1/20 0.38
STAT3 P40763 1/20 0.38
STAT1 P42224 1/20 0.38
KMT2A Q03164 1/20 0.38
CA12 O43570 7/20 0.38
CA1 P00915 7/20 0.38
CA2 P00918 7/20 0.38
CA9 Q16790 7/20 0.38
TP53 P04637 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4163483 0.90 NR3C1 (0.42) NR3C1PGRNR3C2ARSMN1; SMN2
SCHEMBL4163517 0.87 TSHR (0.40) NR3C1PGRNR3C2ARSMN1; SMN2
SCHEMBL4161295 0.82 KMT2A (0.44) SMN1; SMN2ALDH1A1KMT2ALMNA
SCHEMBL4175519 0.82 NR3C1 (0.39) NR3C1PGRNR3C2ARSMN1; SMN2
SCHEMBL4170995 0.81 AR (0.44) NR3C1PGRNR3C2ARSMN1; SMN2
SCHEMBL4172411 0.78 MIF (0.46) NR3C1PGRNR3C2ARSMN1; SMN2
SCHEMBL8352575 0.77 NR3C1 (0.34) NR3C1PGRNR3C2ARSMN1; SMN2
SCHEMBL4175619 0.72 NR3C1 (0.43) NR3C1PGRNR3C2ARSMN1; SMN2
SCHEMBL4160618 0.70 MAPT (0.56) NR3C1PGRNR3C2ARSMN1; SMN2
SCHEMBL4170326 0.70 NR3C2 (0.43) NR3C1PGRNR3C2ARSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2006-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS NR5A1, NR3C2, NR3C1 NR3C1 3/4885PGR 54/4885NR3C2 2/4885
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators NR5A1, NR3C2, NR3C1 NR3C1 3/4885PGR 50/4885NR3C2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.